Across the Global South, hundreds of millions of people live without reliable access to basic healthcare. Too few doctors, too little data, and systems too fragile to scale. However, as Capria Ventures' Francis Perelman outlines, a new wave of AI-native…
Affordability and innovation are usually framed as a zero-sum trade-off in drug pricing debates. Zeba M. Khan, editor-in-chief of ISPOR’s Value & Outcomes Spotlight magazine, makes the case that they…
Can a medicine be considered “available” if it can’t be trusted? As Africa’s manufacturing base expands and its regulatory systems mature, that question is moving to the centre of the…
Five conferences, five continents’ worth of anxiety, one unmistakable pattern: the global pharma industry is being reshaped faster than it can keep up. From Philadelphia to Geneva, Istanbul to Chicago…
In an exclusive interview, Tae-Han Kim, president and CEO of Samsung Biologics, documents his strategy for expanding Samsung’s operations into biologics, and how Samsung Biologics has rapidly become one of the leading Contract Development Manufacturing Organisations (CDMO) in the market in only seven years. Dr Kim also provides his assessment of the CDMO market and the link between insufficient manufacturing…
The Minister of Health of the Republic of Turkey, Dr Fahrettin Koca, provides an overview of the current state of the Turkish healthcare ecosystem, highlighting its opportunities and challenges. He…
The past 5 decades have seen monumental strides in healthcare; from the discovery that aspirin prevents blood clotting to the eradication of smallpox. In this exclusive interview, Thomas Cueni, director…
Germany’s Medical Research Act is almost two years old. Writing in the June/July 2026 edition of DIA Global Forum, Thomas Sudhop, Claudia Riedel and Karl Broich of the Federal Institute…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Simcere securing Greater China rights to RB0026, Immunofoco resubmitting its Hong Kong IPO, Fulcrum merging with Slate Medicines, Henlius…
Sally Epstein looks at why the world’s biggest AI companies are all pivoting towards biopharmaceuticals. Epstein, an entrepreneur in residence at Cambridge Innovation Capital, argues that drug discovery – if…
A sustainable market for generics and biosimilars is the key to lowering the cost of medicine in the US, says John Murphy III, President and CEO of the Association for…
Strong patent portfolios can create substantial commercial value for biopharma companies. As Isobel Barry, partner at life sciences-focused IP firm Carpmaels & Ransford LLP explains, opportunities to patent new small…
Chinese drugmakers are increasingly looking past the NMPA toward approvals in the EU, US, and Australia. Daphne Smyth of Veristat has watched this shift from the front row, guiding sponsors…
See our Cookie Privacy Policy Here
